Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study
Overview
Affiliations
Background: Hyperkalemia is common in patients receiving maintenance hemodialysis. However, few studies have examined the association between serum potassium level and mortality.
Methods: This study used annual cohorts of hemodialysis patients during 2007-2010. To determine hyperkalemia prevalence, monthly hyperkalemia was defined as serum potassium level ≥5.5 mEq/l; prevalence was calculated as a ratio of hyperkalemia episodes to follow-up time, reported separately by long and short interdialytic interval. To determine the impact of hyperkalemia on mortality, patients in the 2010 cohort were followed from first potassium measurement until death or a censoring event; hyperkalemia was defined, sequentially, by potassium levels 5.5-6.0 mEq/l at 0.1 mEq/l intervals. Time-dependent Cox proportional hazards modeling was used to estimate the association between hyperkalemia and mortality.
Results: The 4 annual cohorts ranged from 28,774 to 36,888 patients. Mean age was approximately 63 years, about 56% were men, 51% were white and 44% had end-stage renal disease caused by diabetes. Hyperkalemia prevalence was consistently estimated at 16.3-16.8 events per 100 patient-months. Prevalence on the day after the long interdialytic interval was 2.0-2.4 times as high as on the day after the short interval. Hyperkalemia, when defined as serum potassium ≥5.7 mEq/l, was associated with all-cause mortality (adjusted hazards ratio (AHR) 1.13, 95% CI 1.01-1.28, p = 0.037, vs. <5.7 mEq/l) after adjustment. AHRs increased progressively as the hyperkalemia threshold increased, reaching 1.37 (95% CI 1.16-1.62, p < 0.0001) for ≥6.0 mEq/l.
Conclusions: The long interdialytic interval was associated with increased likelihood of hyperkalemia. Hyperkalemia was associated with all-cause mortality beginning at serum potassium ≥5.7 mEq/l; mortality risk estimates increased ordinally through ≥6.0 mEq/l, suggesting a threshold at which serum potassium becomes substantially more dangerous.
Sharifi M, Mousavi-Roknabadi R, Ebrahimi V, Sadegh R, Dehbozorgi A, Hosseini-Marvast S Arch Iran Med. 2025; 28(1):9-17.
PMID: 40001324 PMC: 11862393. DOI: 10.34172/aim.27746.
Zhang M, Huang G, Bao X, Yang Q BMC Nephrol. 2025; 26(1):46.
PMID: 39885381 PMC: 11780984. DOI: 10.1186/s12882-025-03978-8.
Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis.
Bamforth R, Ferguson T, Tangri N, Rigatto C, Collister D, Komenda P Kidney Int Rep. 2024; 9(11):3226-3235.
PMID: 39534203 PMC: 11551121. DOI: 10.1016/j.ekir.2024.08.007.
The cardiovascular unphysiology of thrice weekly hemodialysis.
Shringi S, Shah A Curr Opin Nephrol Hypertens. 2024; 34(1):69-76.
PMID: 39498607 PMC: 11606746. DOI: 10.1097/MNH.0000000000001037.
Nie Y, Lin L, Yang Q, Hu J, Sun M, Xiang F Biomedicines. 2024; 12(10).
PMID: 39457714 PMC: 11504215. DOI: 10.3390/biomedicines12102402.